Why PMV Pharmaceuticals, Inc.’s (PMVP) Stock Is Down 5.51%
As of Tuesday, July 28, PMV Pharmaceuticals, Inc.’s PMVP share price has dipped by 5.51%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Princeton, New Jersey.
Commentary & Analysis
Why PMV Pharmaceuticals, Inc.’s (PMVP) Stock Is Down 6.77%
As of Friday, July 24, PMV Pharmaceuticals, Inc.’s PMVP share price has dipped by 6.77%, which has investors questioning if this is right time to buy.Jenna Brashear
Why PMV Pharmaceuticals, Inc.’s (PMVP) Stock Is Up 5.38%
As of Friday, July 17, PMV Pharmaceuticals, Inc.’s PMVP share price has surged by 5.38%, which has investors questioning if this is right time to sell.Michael Rose
Why PMV Pharmaceuticals, Inc.’s (PMVP) Stock Is Down 5.75%
As of Thursday, July 16, PMV Pharmaceuticals, Inc.’s PMVP share price has dipped by 5.75%, which has investors questioning if this is right time to buy.Jenna Brashear
Why PMV Pharmaceuticals, Inc.’s (PMVP) Stock Is Up 7.82%
As of Tuesday, July 14, PMV Pharmaceuticals, Inc.’s PMVP share price has surged by 7.82%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Financial Summary
| Share Statistics | PMVP | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $59.2 | $252.6 | 17% |
|
| Shares Out (Mil) | 53.3 | 52.3 | 49% |
|
| Institutional Ownership | 94.5% | 92.1% | 65% |
|
| Float (Mil) | 46.2 | 40.2 | 45% |
|
| Beta | 1.36 | 0.95 | 78% |
|
| Avg Daily Volume (000s) | 235 | 455 | 47% |
|
| Price Change (52-week) |
(21.8%) | 52.9% | 30% |
|
| Growth | PMVP | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (17.7%) | (9.9%) | 22% |
|
| EPS (5yr) | 9.2% | 16.0% | 45 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (14.9%) | (15.6%) | 53% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 2 | 3 | |
| Current EPS | ($0.400) | ($1.515) | ($1.093) | |
| Month Ago EPS | ($0.400) | ($1.515) | ($1.093) | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | ($0.418) | ($1.595) | ($1.103) | |
| Year/Year Chg | 18.3% | 2.4% | (44.3%) | |
| Financials | PMVP | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($78) | ($43) | 12% |
|
| EPS (TTM) | ($1.481) | ($1.600) | 18% |
|
| Operating Cash Flow (TTM) (Mil) | ($75) | ($31) | 7% |
|
| Net Cash Flow (TTM) (Mil) | na | $5 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $5 | 0% |
|
| Enterprise Value (Q1) (Mil) | ($33) | $180 | 1% |
|
| Valuation | PMVP | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.67 | 2.56 | 13% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | PMVP | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (58.6%) | (49.8%) | 10% |
|
| ROE | (63.2%) | (55.5%) | 13% |
|
| Liabilities to Assets | 8.9% | 30.3% | 5% |
|
| F-Score | 2 | 3 | 7% |
|
PMV Pharmaceuticals, Inc. did not pass any screens on 7/31/2026.
